October 7, 2025 – POCTA submitted comments supporting the finalized CLFS payment rates for five tests for neurodegenerative disease (82233, 82234, 83884, 84393, 84394). These tests saw an increase in payment from the proposed rates, aligning with the position POCTA had previously advocated.
